Medivir’s MIV-818 obtains the International Nonproprietary Name fostroxacitabine bralpamide
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) fostroxacitabine bralpamide as the official generic name for the company's patented candidate drug MIV-818, which is in clinical development in primary liver cancer. Medivir's main project, fostroxacitabine bralpamide (MIV-818), is the company’s proprietary candidate drug with a unique mechanism of action, which makes fostroxacitabine bralpamide attractive to be combined with a multitude of other drugs for the treatment